Fig. 4
From: Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
Effect of anti-sCTLA-4 mAb blockade on immune responses to H471-93 peptide isolated from PBMC of healthy donors (left panels) or SLE patients (right panels). PBMC were incubated with H471-93 (20 μg/ml) in the presence of JMW-3B3 anti-sCTLA-4 mAb or an IgG1 isotype antibody (both 10 μg/ml) for 5 days before analysis of cellular proliferation and levels of cell culture supernatant cytokines (IFN-γ, IL-17, IL-10, and sCTLA-4; n = 45 per group; *p < 0.05, **p < 0.01, ***p < 0.001, non-parametric Mann-Whitney U test; median values are shown). CPM counts per minute, IFN interferon, IL interluekin, ns not significant, sCTLA-4 soluble cytotoxic T lymphocyte antigen 4, SLE systemic lupus erythematosus